Verus Capital Partners’s Emergent Biosolutions EBS Stock Holding History

Verus Capital Partners’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83.8K	Hold	10,000	–	–	﹤0.01%	491
2026 Q1	$83K	Hold	10,000	–	–	0.01%	459
2025 Q4	$124K	Hold	10,000	–	–	0.01%	440
2025 Q3	$88.2K	Hold	10,000	–	–	0.01%	413
2025 Q2	$63.8K	Hold	10,000	–	–	0.01%	368
2025 Q1	$48.6K	Hold	10,000	–	–	﹤0.01%	375
2024 Q4	$95.6K	Hold	10,000	–	–	0.01%	357
2024 Q3	$83.5K	Hold	10,000	–	–	0.01%	354
2024 Q2	$68.2K	Buy	+10,000	New	+$43K	0.01%	342
2020 Q1	$5K	Hold	80	–	–	﹤0.01%	1178
2019 Q4	$4K	Buy	+80	New	+$4.34K	﹤0.01%	1329

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Verus Capital Partners's EBS Position: Q2 2026 in Review

Verus Capital Partners held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 10,000 shares worth $83.8K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

Verus Capital Partners first reported a position in EBS in Q4 2019 and has held it in 11 quarters since. The position peaked at $124K in Q4 2025. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Verus Capital Partners held 10,000 shares of Emergent Biosolutions worth $83.8K as of Q2 2026.
Verus Capital Partners left its Emergent Biosolutions share count unchanged in Q2 2026.
Emergent Biosolutions made up ﹤0.01% of Verus Capital Partners's portfolio in Q2 2026, its #491 holding.
Verus Capital Partners first reported a position in Emergent Biosolutions in Q4 2019 and has held it in 11 quarters since.
Verus Capital Partners's Emergent Biosolutions position peaked at $124K in Q4 2025.
195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Verus Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.